This evening we watched Envista drop -5.0% to a price of $25.64 per share. The mid-cap Medical Instruments & Supplies company is now trading -40.07% below its average target price of $42.78. Analysts have set target prices ranging from $38.0 to $46.0 per share for Envista, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 4.0%, and a short ratio of 3.45. Only 0.36% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. Finally, we also note that a significant number of institutional investors are invested in the stock, with 115.8% of Envista's shares being owned by this investor type.
Institutions Invested in Envista
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Blackrock Inc. | 11% | 17,531,103 | $449,497,470 |
| 2023-06-30 | Vanguard Group Inc | 10% | 16,160,708 | $414,360,543 |
| 2023-06-30 | Morgan Stanley | 9% | 14,074,762 | $360,876,889 |
| 2023-06-30 | FMR, LLC | 5% | 8,329,782 | $213,575,605 |
| 2023-06-30 | Massachusetts Financial Services Co. | 5% | 8,294,021 | $212,658,693 |
| 2023-06-30 | Lazard Asset Management LLC | 5% | 7,384,273 | $189,332,755 |
| 2023-06-30 | Harris Associates L.P. | 4% | 6,202,728 | $159,037,942 |
| 2023-06-30 | Dimensional Fund Advisors LP | 4% | 6,047,276 | $155,052,152 |
| 2023-06-30 | Franklin Resources, Inc. | 3% | 5,192,285 | $133,130,184 |
| 2023-06-30 | Ariel Investments, LLC | 3% | 5,117,117 | $131,202,876 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Envista.
